机构:[1]Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, P.R. China[2]Beijing Key Laboratory of Cancer & Metastasis Research, Capital Medical University, Beijing, P.R. China[3]Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff, U.K.[4]Department of Thoracic Surgery, Beijing Xuanwu Hospital, Capital Medical University, Beijing, P.R. China胸外科首都医科大学宣武医院[5]Department of Thoracic Surgery, Key Laboratory for Carcinogenesis and Translational Research Ministry of Education, Peking University Hospital, Haidian District, Beijing, P.R. China[6]Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, P.R. China
Background: Osteopontin (OPN) is known to be involved in the development of certain cancers, including non-small cell lung cancer (NSCLC). However, its role in tumour progression remains unclear. The present study investigated the expression and biological impact of the OPN variant, OPN-a in NSCLC. Materials and Methods: OPN-a splicing variant expression in human NSCLC tissues was analyzed by real-time qPCR and immunohistochemistry (IHC), respectively. The impact of OPN-a on cellular functions of lung cancer cells was also evaluated. In addition, an in vitro model was developed for the assessment of interactions between lung cancer cells and bone tissue. Results: The expression of OPN-a was higher in lung cancer tissues compared to normal controls. OPN-a promoted the malignant phenotypes of A549 cells by enhancing cell-adherent abilities to bone tissues, which could be mediated by the interaction with the cell surface receptor ava3 integrin. Conclusion: OPN-a may represent a bone metastatic factor in human lung cancer, as well as a potential therapy target.
基金:
the National Natural Science Foundation of the People’s Republic of China (81572704),
第一作者机构:[1]Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, P.R. China[2]Beijing Key Laboratory of Cancer & Metastasis Research, Capital Medical University, Beijing, P.R. China
通讯作者:
通讯机构:[*1]Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN Cardiff, U.K.[*2]Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China.
推荐引用方式(GB/T 7714):
CHENGCHENG HAO,YUXIN CUI,MU HU,et al.OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro[J].ANTICANCER RESEARCH.2017,37(5):2245-2254.doi:10.21873/anticanres.11561.
APA:
CHENGCHENG HAO,YUXIN CUI,MU HU,XIUYI ZHI,LIJIAN ZHANG...&WEN G. JIANG.(2017).OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro.ANTICANCER RESEARCH,37,(5)
MLA:
CHENGCHENG HAO,et al."OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro".ANTICANCER RESEARCH 37..5(2017):2245-2254